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ABSTRACT
Chronic pancreatitis in dogs is typically managed with a low-fat diet. Human
research suggests consuming medium-chain triglycerides (MCT) may lower pancreatic
enzyme release compared to consuming long chain fatty acids (LCFA). Twelve healthy
adult colony dogs were fed a meal of cod and rice with either 3% metabolizable energy
(ME) fat (control), high MCT (25% ME MCT oil, 25% ME butter), high saturated LCFA
(50% ME butter), or high unsaturated LCFA (50% ME canola oil) in a 4-period by 4treatment crossover design. Serum concentrations of canine pancreatic lipase
immunoreactivity, gastrin, amylase, cholecystokinin (CCK), cholesterol, triglycerides and
serum activities of DGGR lipase were measured at times 0 (fasted), 30, 120 and 180
minutes post-prandial. Following a 3-or 4-day wash-out period, each dog was assigned a
new diet and the process was repeated for all treatments.
Data was analyzed as a repeated-measures mixed model ANOVA. Post-hoc
pairwise comparisons were run using Tukey-Kramer adjusted p-values. Shapiro-Wilk
tests were used to evaluate residual normality. All statistical assumptions were
sufficiently met. Statistical significance was defined as P<0.05. Of the markers tested,
only serum triglyceride concentrations were affected by treatment, with consumption of
high MCT resulting in lower triglycerides than both LCFA groups at times 120 and 180
minutes (P<0.0001). As expected, the high MCT group also had higher triglycerides
compared to the control (P<0.0001). The type of dietary fat consumed had little acute
impact on most markers of exocrine pancreatic stimulation in healthy dogs.
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CHAPTER ONE
LITERATURE REVIEW

Canine pancreatitis
Physiology of the exocrine pancreas
The pancreas has both endocrine and exocrine functions. The exocrine pancreas
secretes bicarbonate and digestive enzymes for food digestion. Normal pancreatic
secretion activity ensures proper delivery of digestive enzymes, which coordinate food
emptying by regulating stimulatory and inhibitory pancreatic secretion1. The exocrine
pancreas is composed of acinar cells and ductal cells2. The main function of the ductal
cells is for bicarbonate fluid secretion3. Acinar cells constitute more than 80% of the
pancreatic exocrine secretion3; they receive both hormone and neurotransmitter signals
that stimulate the release of digestive enzymes and the precursor forms of digestive
enzymes, known as zymogens, into the intestinal lumen for the digestion of nutrients2.
There are four digestive phases before and during food intake that lead to pancreatic
secretion. They include the cephalic phase, gastric phase, intestinal phase and absorptive
phase. Differentiation between the gastric phase and the intestinal phase can be complex,
therefore they are frequently discussed as one intestinal phase.1 The cephalic phase
occurs before food intake, triggered by sensory input such as the smell and sight of food;
the gastric phase occurs when food enters the stomach, which initiates pancreatic
secretion; the intestinal phase is initiated by acidic chyme entering the duodenum, which
triggers the intestinal phase of pancreatic secretion1. The major pancreatic secretion
response occurs in the intestinal phase, in which stimulation is initiated by hormones and
neurotransmitters such as acetylcholine, serotonin and other neuropeptides1.
Anticipation of intake food, related to the sight, taste, and smell of food, triggers
the vagus nerve to initiate pancreatic secretion, which can account for up to 20-25% of
exocrine secretion related to a meal and may last up to 4 hours in dogs. As food enters the
stomach, gastric secretion of gastrin and gastric acids are initiated and partially digested
food is termed chyme. Gastric chyme is then slowly released into the duodenum for
further digestion and absorption. The presence of nutrients and the drop in intraluminal
1

pH in the duodenum also stimulates pancreatic enzyme release4. Secretin is released from
the basolateral side of the S cells of the proximal duodenum and into the bloodstream
when acidic chyme first enters the intestine. The S cell is located at the mucosal
epithelium on the villi of the duodenum; it is named S cell because of its small size5.
Pancreatic duct cells release bicarbonate rich fluid in response to the secretin to buffer
duodenal pH following the influx of acidic gastric chyme1. Secretin has also been
proposed to stimulate acinar cells to secrete lipase3. Previous research on the infusion of
secretin into rats tail veins by surgical cannulation has demonstrated that it induced an
increase in lipases levels synthesized in the pancreatic lobules after the pancreas was
removed and homogenized6. Cholecystokinin (CCK) is another peptide hormone released
from the basolateral side of the I-cell lining the small intestinal epithelium in response to
a meal. Proteins, peptides, amino acids, and lipids act as secretagogues for CCK with the
response to individual nutrients varying by species containing peptides and lipids. The
pathway of CCK on pancreatic enzyme release is discussed in more detail below.
During the phases of food digestion, the pancreas releases digestive enzymes in
both active and inactive forms, called proenzymes. The pancreas can release some active
enzymes that target carbohydrate, lipid and nucleotide digestion such as amylase, lipase,
and ribonuclease7. The inactive form of enzymes are called proenzymes, which are stored
in zymogen granules. Key proteolytic enzymes, or proteases include trypsinogen and
chymotrypsinogen.
Zymogen granules are specialized organelles that package and secrete exocrine
pancreatic enzymes8. Zymogens are important components within the pancreatic
secretion system, as they provide a protective storage mechanism that prevents active
digestive enzymes from causing cellular damage and autodigestion of the pancreas.
Digestive enzymes remain as proenzymes within in the zymogen granules until they are
released from the pancreas. One example is trypsinogen, the proenzyme of trypsin, is
critical to digestion, and is packed within zymogen granules9. Before activation, trypsin
activity is inhibited by the pancreatic secretory trypsin inhibitor (PSTI) that binds on the
trypsin enzyme active site in pancreatic acinar cells. Enterokinase is a protease that is
secreted from small intestinal mucosa cells. Once trypsinogen and other zymogens reach
2

the duodenum, trypsinogen is converted to trypsin by enterokinase10. This is the
beginning of the enzyme activation process10,11. Trypsin activates the remaining of the
proenzymes released from zymogen granules. These activated enzymes are required for
nutrient digestion10. Normally, the pancreas secretes an adequate amount of digestive
enzymes to facilitate digestion, and the process is regulated by a negative feedback4. The
negative feedback for pancreatic secretion occurs after the activated enzymes are
consumed with dietary protein within the small intestine. The decreased availability of
active enzymes promotes pancreatic enzyme release. Once the meal is mostly digested
and there are fewer proteins available to occupy the proteases, the intestinal surface
detects the rise in protease enzymes and initiates a negative feedback signal to the
pancreas to cease the enzyme release.

Canine pancreatitis
Pancreatitis is the most common disease of the exocrine pancreas in dogs12, which
results from the abnormal and premature release of pancreatic enzymes. Pancreatitis can
be classified as acute or chronic. Acute pancreatitis occurs due to inappropriate activation
of enzymes near or within the pancreas before zymogens reach the small intestine. Early
activation of proteases can cause autodigestion of the pancreatic acinar cells and lead to
inflammation and/or necrosis of the pancreas and /or nearby tissues13. Clinical signs of
acute pancreatitis in dogs include cranial abdominal pain, vomiting, depression, anorexia,
and weakness13,14. Severe cases may involve cardiovascular shock, disseminated
intravascular coagulation (DIC), multi-organ failure, and death14.
Chronic pancreatitis is defined as continuous or recurring inflammation of the
pancreas with irreversible morphological changes that cause pain or permanent loss of
function15 in both exocrine and endocrine aspects. Chronic and ongoing inflammation
and fibroses may eventually lead to exocrine pancreatic insufficiency (EPI) or diabetes
mellitus (DM)15. Dogs with chronic pancreatitis often present with intermittent, mild to
moderate gastrointestinal signs, episodic anorexia and/or food aversion. Dogs with
chronic pancreatitis can also have acute flares with vomiting, diarrhea, and lethargy
similar to acute pancreatitis15.
3

In humans, acute or chronic pancreatitis cases are caused by complex interactions
between genetic and environmental factors16; however, the etiology of pancreatitis is
often unclear in dogs16. Risk factors for developing pancreatitis can be present in any age,
breed, or sex of the animal. Some dog breeds are more likely to develop chronic
pancreatitis. A post-mortem study of canine pancreatitis from the UK found that Cavalier
King Charles Spaniels, English Cocker Spaniels, Boxers, and Collies were highly
represented in the study17,18. Some case studies found several USA breeds who appear at
greater risk for chronic pancreatitis, such as the Yorkshire terrier and miniature
schnauzer.19-21 Beyond ages and breeds, certain health conditions are also cited risk
factors. For example, dogs with concurrent endocrine disease, hypercalcemia, and obesity
are at risk of developing chronic pancreatitis22. Other risk factors include previous
surgeries, having been neutered or certain medications, or dietary indiscretion
spayed20,21,14.

Diagnosis
Clinical diagnosis of canine chronic pancreatitis can be challenging. Dogs with
pancreatitis may present with a variety of non-specific clinical signs such as anorexia,
weakness, vomiting, diarrhea, depression and/or abdominal pain14,22.
Historically, the serums amylase and lipase were used to diagnose pancreatitis in
dogs22, but these tests haven fallen out of favor because they lack sensitivity and
specificity. Recently, pancreatic lipase immunoreactivity (PLI) has been used more
widely for clinical diagnosis22. A study published by Cridge et al. found that, in
comparison to histopathology samples, serum amylase was a less sensitive marker for
diagnosing pancreatitis than canine specific pancreatic lipase immunoreactivity (Spec
cPLI or cPLI)23. By utilizing 22 samples from the histopathology lab, Texas A&M
University found that serum amylase has a 18.2% sensitivity for detecting pancreatitis,
which is significantly lower than the Spec cPLI test result of 63.6% sensitivity24. Another
study reported by McCord et al. found that in 84 dogs with clinical pancreatitis, the
serum amylase had a specificity of 76.7%-80.6%, while the Spec cPLI test had between
80.5%-88.0% specificity25. Therefore, the serum amylase has no longer been considered
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as a routine diagnostic method for canine pancreatitis when compared to cPLI23. Details
of cPLI will be discussed further below.
Diagnostic imaging in the form of abdominal ultrasound and radiography are
other tools used to aid in the diagnosis of both acute and chronic canine pancreatitis23.
Abdominal radiography can also help rule out other acute abdominal diseases during
examinations26. Some other imaging methods are contrast-enhanced ultrasonography,
elastography, computed tomography angiography and magnetic resonance imaging23. But
Cridge et al (2020) has recommended performing quantitative pancreatic lipase assay in
addition to abdominal ultrasound27.

Nutritional Management of Chronic Pancreatitis
Proper nutritional support is key for reducing the frequency and/or severity of
chronic pancreatitis. Feeding a low-fat diet is recommended to human patients with
chronic pancreatitis28. Previous research in dogs also suggests feeding a low-fat diet
reduces post-prandial pain associated with pancreatitis17. This reduction in pain may be
the result of less enzyme release from the pancreas since fat is a potent stimulator of
CCK28. The mechanistic benefit for feeding a low-fat diet is to reduce CCK stimulation
of the inflamed pancreas. Because dietary fatty acids are potent secretagogues of CCK
secretion in dogs, low-fat diets minimize CCK secretion and subsequent pancreatic
stimulation and further enzyme release. Initially, the pain of chronic pancreatitis results
from the exocrine pancreatic secretion activity and hyperstimulation, leading to the
increased pressure of pancreatic duct and tissue29,30. In addition, hyperlipidemia is a
known risk-factor for pancreatitis and feeding a low-fat diet can decrease serum lipid
levels 31.
Protein peptides and free amino acids are also important stimuli of pancreatic
enzyme secretion and carbohydrates have a negligible effect. Therefore, avoiding foods
with excess protein levels and providing moderate carbohydrate intake is desired. In dogs
with chronic pancreatitis, dry matter (DM) protein composition for dogs should be
around 15-30% in calories densities32. It is critical to balance the protein composition to
other nutrients in the diet. Protein is one of the three essential nutrients (carbohydrate,
5

lipids, protein). Protein can stimulate protease enzyme secretion, and protease is the most
responsible for autodigestion of the pancreas and the inflammatory process33. However, if
the diet has very minimal protein content, it may cause deficiencies of other nutrients. For
example, vitamin B12 deficiency34.
As dietary protein enters into the stomach it triggers the release of gastrin to
stimulate the release of gastric acid. Gastrin also stimulates the exocrine pancreas to
release proteases in anticipation of chyme entering the duodenum. In the duodenum,
CCK is a major hormone promoting more protease secretion from the pancreas. Gastric
distension also stimulates mechanoreceptors to provide neuronal signals to the vagal
nerve to stimulate parietal cells, resulting in exocrine pancreatic secretion as well35.

Markers of exocrine pancreatic stimulation
Cholecystokinin (CCK)
Cholecystokinin is a peptide hormone mainly produced by I-cells in the lining of
the duodenum and proximal jejunum. After a meal containing fatty acids and proteins
lipids, peptides and amino acids reach the small intestine and act as a cellular signal for Icells to synthesize and release CCK. CCK is released from the basal side of the I-cell into
the bloodstream36. In the peripheral circulation, CCK interacts with CCK-A receptor at
the gallbladder smooth muscle cells, the binding process is transported by G-protein
coupled receptors with in the cytosol37. G-protein coupled reaction mediate calcium
signaling by increase intracellular calcium level resulting in gallbladder contraction and
secretes of bile and bile salts into the intestine. CCK binding to CCK-A receptor on
pancreatic acinar cells initiates the release pancreatic enzymes through G-protein coupled
receptor and calcium mediates pathway; both bile and pancreatic enzymes help to digest
fatty acids nutrients in the small intestine38. CCK continues being secreted until all the
absorption is complete and nutrients stimulation of I-cells has ceased.
CCK secretion is initiated by fatty acids and protein intake. Nonetheless, small
amounts of CCK are released during the cephalic phase by the sight, smell or taste of
food. A study found a CCK peak around 45-90 minutes after food intake for dogs39.
Other studies reported that in healthy dogs, CCK levels peak 1 hour following
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administration of corn oil40. This later study utilized long-chain fatty acids as a potent
stimulator of canine CCK and pancreatic enzyme release.
CCK has four receptors: CCK-A receptor (CCKAR), CCK-B receptor (CCKBR),
gastrin, and CG-4 receptors. CCKAR and CCKBR are the major receptors, in a human
research, both receptors located in the upper gastrointestinal tracts has separate regulatory
role of gastrin and CCK in terms of morphological and biochemical41. CCKAR has high
affinity for sulfated CCK only42. There are two CCKAR types: one located in the
pancreas, and the other one at gallbladder38. CCKBR are found on cells throughout the
central nervous system; some are located at parietal cells in the gastrointestinal system as
well. CCKBR is a receptor not only for CCK but also for gastrin binding38,43.
There are several forms of CCK, and the most abundant forms of CCK found in
dogs are CCK-58, K-39, CCK-33, and CCK-844,45. These forms are classified based on
the number of amino acids within the molecule. CCK-8 has 8 amino acids, the 8 amino
acids are structural conserved binding site to the CCK receptor; whereas CCK-58 has a
longer sequence, and the extra 50 amino acids may hinder its binding sterically38. CCK is
primarily secreted from I-cells on the small intestine, but it has been found that some
CCK is expressed in the brain and neurons36. Aside from food stimulation causing the
release of CCK from duodenum, CCK is also released from the dorsal vagal complex
within the brainstem during the cephalic phase of the food digestion process. Both the
brain and digestive organs have CCK receptors. The forms of CCK that exist in the brain
and gut are different: CCK-8 is the primary form found in brains of dogs. CCK is found
in highest concentration within the intestine. CCK-58 is the most abundant form, other
abundant forms are CCK-39, CCK-33, and CCK-8. 44. CCK-58 is the major form of
CCK, with 80% of immunoactivity in some species38. CCK-58 is the most abundant form
of CCK in dog blood46 but is degraded rapidly in blood plasma with a half-life of 2.6
minutes47.
Because CCK is secreted within the brain and small intestine, to measure total
CCK release, require sampling of the cerebrospinal fluid and jejunoileal mucosa48. In
reality, measuring blood CCK is the most practical and adequately represents the foodstimulated CCL release into the blood following secretion. A challenge in accurately
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measuring is that CCK is a very small amount peptide hormone and highly sensitive to
the plasma protease degradation after release. The half-life time of CCK is around 2.6
minutes in dogs39,47. The average basal concentration is around 2.70.2 pM and reaches a
maximum of 5.00.7 pM after a normal meal39.
CCK is an important hormone in the gastrointestinal digestive process. Several
methods have been used to measure circulating levels of the hormone, each with their
advantages and limitations. Liddle (2011) describes a reliable CCK assay antibody as
being able to distinguish at least three amino acid between the CCK and gastrin
sequence49. Radioimmunoassay (RIA) is sensitive immunoassay technique that uses
radiolabeled molecules for measuring small amounts of peptide; the level can be as low
as picograms in units. The principle of RIA is that of competitive binding, which involves
using a fixed number of antibodies to bind with labeled antigens called “tracer” and
unlabeled antigens from the sample or standards. Once antigens and antibodies bind, the
labeled tracer is detectable by the radioactive counter. Higher rates of the tracer activity
indicate lower concentration of the sample antigen, and vice versa. With RIA testing,
high affinity antibodies are required for testing a low concentration of CCK in some
serum samples. Even though RIA has the advantage of high sensitivity, it requires
specialized equipment and the use of radioactive materials.
Enzyme-linked immunoassay (ELISA) is a commonly used assay technique
available for measuring CCK that is also based on antigen-antibody reaction. Rather than
using radioactive reagents, ELISA relies on the activation of a chromophore or
fluorescent compound to create a colorimetric signal. The two most commonly used
types of ELISA are competitive ELISA and sandwich ELISA. The competitive ELISA
combines an incubated mixture of sample antigen and test antibody to an antigen coated
substrate. Samples with a high antigen concentration will bind more test antibodies,
causing less binding of the reference antigen. Any unbound antibody is removed through
plate washing. Depending upon the antigen concentration in the sample, A second
enzyme-linked antibody that has the same binding affinity as the sample antibodies is
applied to a pre-coated antigen well. A chromophore or fluorescent substrate is then
added such that antibody-bound enzyme activates a substrate to a detectable color signal,
8

when the secondary antibody successfully binds to the test antibody. More color on the
well or solid substrate indicates lower levels of sample antigen were present to bind the
test antibody during incubation.
Sandwich ELISA’s utilize pre-coated capture antibodies on the well surface.
Sample antigens are added and bind the capture antibodies. After washing the plate to
remove unbound antigen, detecting antibodies are applied that also bind the sample
antigen. Following a second wash to remove unbound detection antibody, a colorimetric
chemical such as tetramethylbenzidine (TMB) is added and a blue color develops
proportionately to amount of sample analyte present. While RIA is generally more
sensitive than ELISA, the simplicity of running ELISA assays and avoiding radiation
hazards makes it a more practical approach in many laboratories.

Gastrin
Gastrin is a linear peptide hormone that is mainly secreted from the G-cells in the
gastric mucosa on the stomach pyloric antrum after food intake and stimulates the
secretion of hydrochloric acid (HCl) from the stomach to initiate digestion. The major
gastrin forms found in dogs are gastrin-34, gastrin-17, and gastrin-14, with the
concentration found in gastric fluid decreasing, respectively50. Gastrin is produced by the
G cell located in the pyloric antrum, and the secretion is primarily stimulated by dietary
protein43. Some G cells are also located within the duodenum and pancreas51. It is
possible that gastrin stimulates pancreatic acinar cells to increase enzyme secretion to aid
digestion.
The structure of gastrin is similar to CCK with both having common binding
motifs. In mammals, only gastrin and CCK have the same carboxyl terminal42 (Figure 1).
CCK binding to the CCK-A receptor primarily stimulates gallbladder contraction and
pancreatic enzyme secretion. The CCK-B receptor is predominantly located at the brain,
is less selective, and binds to gastrin42, gastrin and CCK can both bind to the CCK-B
receptors.43. A clone experiment from a parietal cell shows that the gastrin receptor and
the CCK-B receptor are identical52. Due to the similarity between gastrin and CCK, it is
important to consider that CCK may have cross-reactivity with gastrin since they have
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very similar molecular structure and binding receptors. Therefore, cross-reactivity with
gastrin is an important feature is to consider in validating CCK assays53. Serum gastrin
measurement can be done using radioimmunoassay or chemiluminometric assays which
appear less sensitive than the radioimmunoassay54. The normal dog gastrin level is
around 10-40ng/L55, which is 3.46-13.85 pM.

Canine specific Pancreatic lipase (cPLI)
Lipases are a type of enzyme that help break down dietary fats into smaller fatty
acids during digestion. Lipases are mainly produced from the stomach and pancreas, and
to a lesser amount are secreted by lingual serous glands56 to break down dietary fats into
fatty acids57. Pancreatic lipase (PLI) is an enzyme secreted by the pancreas that is mainly
responsible for aiding the digestion of triglycerides58. Pancreatic lipase can also stimulate
the release of CCK40, further promoting it’s excretion into the duodenum. When dietary
fatty acids arrive at the duodenum, they are broken down into fatty acid droplets by a
combination of pancreatic lipase anchored by colipase to bile salts. This allows further
emulsification of the lipid droplets into monoacylglycerides and free fatty acids for
absorption59.
Because serum lipases can be elevated for a variety of reasons and released from
different tissues in the GI tract60, measuring the total serum lipase yields poor specificity
for diagnosing pancreatitis. The lipase secreted from the pancreas has a unique amino
sequence that allows differentiation from other lipases in the body.61 Canine pancreatic
lipase (cPLI) is an immunoreactivity assay that provides a more specific measure of
pancreatitis in dogs since it only measures the lipase secreted from pancreas62. In the case
of active pancreatitis, high concentrations of pancreatic lipase are released into the
circulation23. In the immunologic cPLI assay, antibodies are used to test the lipase
concentration by binding with antigens using ELISA23. The validity of the cPLI assay to
detect pancreatitis was compared the gold standard of pancreatic histology. To ensure the
specificity, results were also validated using dogs with exocrine pancreatic insufficiency
(EPI) to test pancreatic lipase levels. In a study comparing 25 dogs with EPI to controls,
investigators found a median concentration about 0.1 μg/L in the dogs with EPI,
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compared to 16.3 μg/L in the control group. This study demonstrated that cPLI has a high
specificity for pancreatic lipase compared to lipase released from other tissues23.
Radioimmunoassay and ELISA are both methods of measuring cPLI. Both analytical
methods are sensitive, accurate and clinically applicatable61. A normal dog has serum
cPLI levels that range between 0 to 200g/L63; serum levels higher than 200g/L is
suggests pancreatitis. Normal dogs reach approximately 75.2g/L after a standard meal
intake64.

DGGR lipase
In addition to the immunologic lipase assay, another common method for
measuring lipases is by catalytic assay23. This method measures the hydrolysis of
substrate by potential lipases, and uses colorimetric reaction to detect enzyme activity65.
Using 1,2-diglyceride(1,2DiG) as the substrate of an analytical assay, hydrolysis by
serum lipase can be determined serum lipase levels.66 The assay requires complex and
multistep colorimetric reaction, and previous tests indicate that the sensitivity of serum
lipase is less than 60%67 because 1,2DiG hydrolysis is not-specific to pancreatic lipase68.
A better substrate was developed in 200168 which is 1,2-o-dilauryl-rac-glycero-3-glutaric
acid-(69-methylresorufin) ester (DGGR). This substrate has higher sensitivity, higher
pancreatic-enzyme-specificity and is more selective compared to 1,2DiG65. DGGR assay
works as a substrate when cleaved by lipase to become a reliable assay for acute
pancreatitis testing in dogs .65 After DGGR became widely used in human pancreatitis
diagnosis, interest in its usage within veterinary medicine grew. The between assay
reliability experiment found that DGGR assay measured the within-run and within-day
coefficient of variation (CV) is less than 3% and the day-to-day CV is 14%65,69, this
provides assurance of the DGGR assay reliability in measuring lipase activity in the
serum of dogs. There was an “statistical agreement” established between cPLI and
DGGR lipase assay, where the calculated Cohan’s kappa coefficient value ( value) fell
into the 95% confident intervals, indicating that the amount of agreement between DGGR
lipase and cPLI is modest70,71. Therefore, DGGR lipase assay does not have as strong
predictive value for pancreatitis compared to cPLI, but it can still be considered a
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reasonable screening test, especially for the rapid diagnosis of acute canine pancreatitis72.
When using DGGR lipase clinically, it is better to measure cPLI level and compare the
results of the two tests simultaneously.

Amylase
Amylase is a cytoplasmic enzyme that is made and secreted by the intestines and
pancreas of dogs. Amylase is primarily released from the pancreas and hydrolyses the
starch in the intestine during digestion. Amylase was initially used as a biomarker of
acute pancreatitis, but it has been found suboptimal in 197023,73. Amylase is not only
secreted from the pancreas, in dogs, amylase is secreted from the intestine. The study
shows that serum amylase is increased both during and following damage to the pancreas
in dogs. However, serum amylase does not remain in serum or plasma as long as
pancreatic lipase following injury.74 Amylase is no longer considered a valid marker for
pancreatitis testing due to variable levels in disease and lack of organ specificity23. A
study by Strombeck et al. surveyed 713 cases of dogs, which included healthy dogs and
dogs with suspected pancreatitis75. They measured serum lipase and serum amylase and
found serum amylase concentrations are essentially the same between normal and dogs
with suspected pancreatitis75. This finding led them to conclude that serum amylase is
only valuable when compared with serum lipase concentrations when diagnosing
pancreatitis75. Even though amylase is no longer a reliable marker in the diagnosis for
pancreatitis, it is secreted from the pancreas in response to carbohydrate intake and may
be used to detect some degree of exocrine pancreatic function. When considering changes
in serum amylase levels, it needs to be considered that increased amylase can be caused
by renal, hepatic, intestinal, and neoplastic diseases, as well as other non-pancreatic
conditions14.

Dietary fatty acids
General information
Dietary fatty acids are fatty acids sourced from fruits, vegetables, animal tissues,
seeds, nuts, etcetera. The majority of fats are composed of long-chain fatty acids; the
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main categories of dietary fats include saturated, mono-unsaturated, and
polyunsaturated76. Dietary triglycerides are the lipid molecules that have three fatty acids
chain attached to the glycerol backbone; in this case, the number of carbons on the
backbone are determinants of fatty acid classification. These classifications include short
chain (<6 carbons) triglycerides (SCTs), medium chain (6-12 carbons) triglycerides
(Figure 2), and long chain (>12 carbons) triglycerides77 (Figure 3). The fatty acid
component of triglycerides may or may not contain double bonds. Saturated fatty acids
are defined as “saturated” because they do not contain carbon-carbon double bonds as
bonds are saturated with electrons. Unsaturated fatty acids contain at least one double
bond (monounsaturated fatty acids) or multiple carbon-carbon double bonds
(polyunsaturated fatty acids or PUFA)77.
Triglycerides (TAG) are usually a typed of long-chain fat that have three fatty
acids attached on a backbone with three carbons. Dietary triglycerides are hydrolyzed by
pancreatic lipase to glycerol, free fatty acids, mono and diglyceries78. In human patients,
triglyceride-induced pancreatitis is one form of the disease and is associated with
triglyceride levels over 1000mg/dL79. In dogs, the association between chronic
pancreatitis and hyperlipidemia is still unclear, but it has been suggested that they are
bidirectional80. Testing serum triglycerides levels provides a reference of dietary intake,
hormonal disorders, and the effectiveness of pancreatic lipase secretion and digestion of
TAG. A normal dog’s triglycerides reach peak level around 2 hours to 4 hours
postprandially81.
Cholesterol is an unsaturated alcohol compound as the precursor of various
steroid hormones82. Cholesterol also provides fundamental structural functions in cell
membranes and associated with lipoprotein composition. Depending on different types of
lipoproteins, high density lipoprotein (HDL) contains higher protein and lower
cholesterol composition, whereas very low-density lipoprotein (VLDL) contains much
higher cholesterol composition. It has been demonstrated in people with acute
pancreatitis that cholesterol levels reveal a U-shape curve in response to treatment. In the
648 cases of acute pancreatitis in the study, those with low fasting blood cholesterol and
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high fasting blood cholesterol level had higher incidence of protracted hospital stay than
patients with normal cholesterol level patients83.
Following a meal, fats containing triglycerides and cholesterol are digested and
absorbed into the bloodstream. They are then packed and transported in plasma by
specific lipoprotein rich in triglycerides such as VLDLs84.
Another type of fatty acid is medium-chain fatty acids, or medium-chain
triglycerides (MCT). Historically, MCT has been used to treat some gastrointestinal
disorders. Compared to long-chain triglyceride (LCT), MCT have a lower molecular
weight and higher water solubility. MCT only contains saturated fatty acids; therefore, it
has no carbon-carbon double bonds in the molecule. MCT are rapidly digested and
absorbed. Thus, it has been used for certain gastrointestinal disorder patients with
impaired fat digestion and absorption85. For instance, MCT has been used to manage fat
intake in people with pancreatic insufficiency. In a study, 8 enzyme-insufficient patients
with EPI consumed 69% MCT as fat sources for 10 weeks. The results of this diet
showed minimal CCK released and a decrease of post-prandial abdominal pain77,86.
Similarly, past studies have been conducted in people consuming either MCT or normal
LCT. These studies found that when administrated isocalorically, MCT resulted in little
CCK release compared to LCT administration. These researchers concluded from that
MCT can help reduce exocrine pancreatic secretion compared to LCT87,88.

MCT Digestion
Usually during the digestion of LCTs, when fatty acids reach the stomach and
duodenum, the I-cell of the small intestine secretes cholecystokinin (CCK) to stimulate
pancreatic enzyme release and help digestion. CCK promotes bile secretion from the
gallbladder to help emulsify LCTs to smaller droplets for digestion77,89. Pancreatic lipase
are the fat-splitting enzymes that are secreted by the pancreas. With the aid of co-lipase
secreted from the pancreas, lipase cleaves triglycerides at the surface of emulsified fat
droplets, helping fatty acids, cholesterol and monoglycerides form into micelles.
Micelles diffuse through the unstirred water later of the intestine and are absorbed by the
small intestine later to be packed into chylomicrons for future fatty acids transport,
14

storage, or energy use. However, MCT digestion is simpler and more rapid due to its
features. MCT does not stimulate CCK87,89; instead, MCT are passively transported and
absorbed directly from the small intestine lumen into the portal vein without
emulsification or cleavage77,85. They are then rapidly oxidized in the liver without
secretion of pancreatic enzymes90, or being stored in the form of LCT in the liver90.
MCT has been used for patients who suffer with fat digestion problems85. In this study,
the role of MCT oil in CCK secretion, pancreatic exocrine stimulation, and lipid
digestion is being considered for dietary management of pancreatitis in dogs.

Pancreatic stimulation by different fatty acids
When animals eat dietary fatty acid, lingual lipase is secreted from the tongue
while gastric lipase is secreted from the stomach for early digestion of fat; however, the
major digestive process occurs in the small intestine91. After partially digested fat reaches
the small intestine, the stimulation of the I-cell in the small intestine is initiated to secrete
CCK. CCK binds to receptors on the gallbladder and pancreas to secrete bile acids and
pancreatic lipase, respectively, and to aid in TAG emulsification and hydrolysis. With the
pancreas also secreting bicarbonate, TAGs are broken down into free fatty acids and
monoglycerides. Then, they are packed by bile salts and become into micelles91. Because
TAG is hydrophobic, in order to be absorbed across the hydrophilic unstirred water layer
of the intestine, the fatty acids from TAG hydrolysis are arranged into water soluble
micelles. The micelles usually contain free fatty acids, 2-monoacylglycerol, cholesterol
and cholesterol ester, which are released into enterocytes of distal small intestine once
micelles interact with the brush border of the small intestine. Next, re-esterification of
fatty acids to TAG takes place within the enterocyte followed by repackaging into
chylomicrons which transport, TAGs, cholesterol esters, cholesterol, and other nonpolar
lipids through the circulation.
The most important difference between MCT and LCT is that LCT as typical
dietary fatty acids require emulsification, hydrolysis, micelle transport and repackaging
prior to release into the portal system while fatty acids shorter than 1-12 carbons, once in
the mucosal cell may be directly absorbed into the portal circulation. Before using LCFs
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as an energy source, they must be repackaged into chylomicrons in the form of
triglycerides. MCTs are rapidly absorbed into the enterocytes and bypass the need to be
packed into chylomicrons. A previous experiment shows that humans who took MCT as
their fatty acids source had lower levels of triglycerides and cholesterols in their blood
compared to those consuming LCT92, demonstrating the effect on lipid metabolism. This
provides a mechanism of why MCT intake can decrease serum triglycerides compared to
an isocaloric LCT diet.
After consuming a meal, fatty acids reach the small intestine waiting to be
emulsified by bile acids and hydrolyzed by pancreas secreted lipase. Pancreatic lipase
plays an important role in this process, predominantly in the hydrolysis of triglycerides. It
is required for dietary triglyceride digestion93,94.
Through both direct and indirect action, dietary fats stimulate the release of
pancreatic enzymes to promote their digestion. However, the role of fatty acid length and
composition on pancreatic stimulation in dogs is unclear. A previous study in rats
suggested that feeding a high MCT diet resulted in lower pancreatic lipase activity
compared to feeding low and medium MCT levels58. It was also studied in infants that
MCT can decrease pancreatic lipase secretion compared to LCT58. These findings are
promising when considering the impact of fatty acid length on the release of CCK and
markers of pancreatic lipase secretion (e.g., cPLI) in the dog. Therefore, we propose that
a high MCT diet will have decreased cPLI serum levels as a marker for decreased
pancreatic enzyme release.
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CHAPTER TWO
Impact of fatty acid composition on markers of exocrine pancreatic
stimulation
Introduction
Pancreatitis is a common disease in dogs and is characterized by the aberrant
release of pancreatic lipase and protease enzymes. In normal pancreatic function, several
intestinal hormones stimulate the release of pancreatic enzymes in response to dietary
protein and fat. Typical nutrition plans for chronic pancreatitis in dogs involve balancing
protein and limiting fat level in the diet to reduce pancreatic enzyme secretion32.
However, there are some practical drawbacks to using low-fat diets for long-term
pancreatitis management. Because fat is more calorically dense than protein and
carbohydrates, low fat diets typically have a lower caloric density than traditional diets.
In addition, dietary fat and protein are highly palatable to dogs and formulating diets that
are moderate in protein and low in fat can reduce voluntary food intake. Consequently, it
can be difficult to maintain ideal body weight if patients consume the diet for a long time.
Understanding the effect of various fat sources on pancreatic stimulation could provide
better dietary management of canine pancreatitis by increasing the caloric density of
foods for dogs with chronic pancreatitis.
Most dietary fats are in the form of long-chain fatty acids (LCFA) and are potent
stimulators of pancreatic enzyme release88. Long-chain fatty acids (LCFA) are the
primary dietary form of lipids and contain at least 14 carbons. The fatty acid component
of triglycerides may or may not contain double bonds. Saturated fatty acids do not
contain carbon-carbon double bonds whereas unsaturated fatty acids contain at least one
double bond (monounsaturated fatty acids) or multiple carbon-carbon double bonds
(polyunsaturated fatty acids or PUFA). Medium-chain triglycerides (MCT) contain
shorter chain fatty acids with 6 to 12 carbon atoms. Due to their smaller size and
lipophilic properties, MCT can be rapidly absorbed into enterocytes and the portal
circulation. In addition, research in humans suggests MCT do not stimulate the exocrine
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pancreas or cholecystokinin (CCK) release to the same degree as LCFA87. CCK is a
peptide hormone that is mainly produced by I-cells in the lining of the duodenum to
stimulate exocrine pancreatic enzymes release. In a study of eight healthy adult humans,
infusion of MCT into the stomach did not significantly increase amylase, lipase, or
bilirubin within the duodenum. In contrast, LCFA significantly increased the release of
all three. In the same study, plasma CCK was significantly higher than the baseline with
the LCFA administration with MCT having no effect on CCK concentrations87. The
impact of MCT on the stimulation of the exocrine pancreas has not been studied in dogs.
Canine-specific pancreatic lipase (cPLI) is a serum marker that reflects the
amount of pancreatic lipases released into circulation. cPLI is often used to diagnose
active pancreatitis in dogs95. Cholecystokinin (CCK) is an intestinal hormone that
primarily stimulates pancreatic enzyme release and gallbladder contraction. Gastrin is a
similar molecule to CCK; however, gastrin is released by the stomach in response to
gastric distension. Both gastrin and CCK stimulate acinar cells of the exocrine pancreas
to release digestive enzymes43. Measuring CCK, gastrin, and cPLI in healthy dogs
following a meal may provide insight into the nutrient components that trigger
pancreatitis.
The goal of this study was to evaluate markers of exocrine pancreatic stimulation
in dogs eating a high MCT diet compared to diets high in saturated or unsaturated LCFA
and a low-fat control diet. Additionally, this study assesses the role of fatty acid
saturation in pancreatic stimulation. Determining whether differences exist between
saturated and unsaturated LCFA is valuable since these are the main fats found in a
typical diet. A human study conducted by Beardshall (1989) suggested that consumption
of mono and polyunsaturated LCFA resulted in greater secretion of CCK compared to
saturated fatty acids96. High levels of unsaturated fatty acids, but not saturated fatty acids,
also induced intra-cellular trypsin activation and cell damage of pancreatic acinar cells in
vitro.97 Thus, this study considers that consumption of unsaturated fatty acids may result
in more pancreatic stimulation compared to saturated fats in dogs. Finally, post-prandial
concentration of cPLI in healthy dogs has not been evaluated and is another aim of this
study.
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Material and Methods
Experimental design
Utilizing a four-period by four-treatment crossover design, this study compared
the concentrations of serum CCK, gastrin, and cPLI in twelve healthy, adult research
dogs consuming meals with varying fatty acid content and composition. Four dietary
treatment groups were studied, consisting of a control diet with minimal fat, a high long
chain saturated fatty acid (LCSFA) diet with approximately 50% of metabolizable energy
(ME) from butter, a high long chain unsaturated fatty acid (LCUFA) diet with
approximately 50% ME from canola oil, and a high MCT diet containing approximately
25% ME from MCT oil and 25% ME from butter. Following a 24 hour fast, baseline
blood samples were collected and each dog was fed a test diet. Blood sampling was
repeated at 30, 120 and 180 minutes post-prandial. Following a 2-3-day wash-out period
on the regular maintenance diet (Purina ONE® Lamb & Rice Formula Dry Dog Food,
Nestlé Purina PetCare Company, St. Louis, MO) (Table 2), each dog was assigned a new
treatment diet and the process was repeated until all dogs received all treatments (Figure
4).

Experimental subjects
Following approval by the University of Tennessee’s Institutional Animal Care
and Use Committee (IACUC 2862), twelve healthy, adult purpose-bred research beagles
were enrolled in the study. All dogs were determined to be healthy upon physical
examination and had received a complete blood count, chemistry panel, and urinalysis
within the previous 12 months. Each dog was randomly assigned to one of 4 dietary
treatment groups by blindly drawing each dog’s name from a bowl.

Diet design
All treatment diets were made with a base of Pacific cod skinless filets (Great
Value, Bentonville, AR), Mahatma extra-long enriched rice (Riviana, Houston TX), and
fat free Swanson® chicken broth (Campbell Soup Company, Camden, NJ). The cod and
rice were prepared based on the manufacturer’s directions then combined and frozen. Fat
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treatments and broth were added prior to feeding. The LCSFA group contained 50% ME
from butter (Land O’Lakes, Saint Paul, MN). The LCUFA group contained 50% ME
from canola oil (Great Value, Bentonville, AR). The high MCT group contained 25% ME
from MCT oil (NOW®, Bloomingdale, IL) and 25% ME from butter. The MCT
treatment group contained both MCT and butter due to palatability issues when feeding
50% ME from MCT oil. Dietary nutrient profiles of each group are listed in table 1.
Test meals provided 50% of a dog’s daily energy requirements (DER) to mimic a
twice daily feeding schedule. The control diet provided approximately 25% of DER since
it contained no added fat source. The DER of each dog was calculated based on the
formula:130*[BW(kg)^0.75]98.

Sample collection and analysis
Jugular blood samples were collected in a 2mL vacutainer serum clot activator
tube (Greiner Bio-One North America Inc. Monroe, NC). Samples were immediately
placed on ice and centrifuged in a refrigerated centrifuge at 3000x for 10 minutes to
separate the serum. The serum was stored in cryogenic vials (Premium Vials, Tullytown,
PA) and frozen at -80°C before being shipped on dry ice to the Texas A&M University
(TAMU) Gastrointestinal Laboratory for sample analysis. The cPLI was measured using
Idexx Spec PL ELISA kit (IDEXX Laboratories, Inc., Westbrook, ME). Gastrin
measurement was conducted using Siemens Immulite XPi (Siemens Medical Solutions
USA Inc. Malvern, PA). DGGR lipase was tested using Sentinel Lipase NG assay (Via
Robert Koch, 2 - 20152 Milano, Italy). Amylase, triglycerides and cholesterol were
measured using Beckman Coulter reagents (Beckman Coulter Inc., 250 South Kraemer
Boulevard, Brea, CA). DGGR lipase, amylase, triglycerides, and cholesterol were run on
a Beckman AU480 (Beckman Coulter Inc., 250 South Kraemer Boulevard, Brea, CA).
CCK measurements occurred at the primary institution using a canine-specific
ELISA (ELISA kit 2885300, MyBioSource, San Diego, CA). The manufacturer-reported
sensitivity was <4.0pg/mL, intra-assay variation 5.6%, inter-assay variation 7.9%.
Gastrin cross-reactivity of the CCK ELISA kit was also tested through spike and
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recovery with Biomatik dog recombinant gastrin #RPU54348 (Biomatik USA LLC,
Wilmington, DE). Recombinant gastrin was tested in the same concentrations as the CCK
standard curve and didn’t show cross-reactivity; the CCK ELISA kit has not been tested
with natural gastrin.
Statistical analysis
A power analysis was performed using PASS 2021 (Power Analysis and Sample
Size Software (2021). NCSS, LLC. Kaysville, Utah, USA, ncss.com/software/pass).
Based on detecting two-fold difference in cPLI, a 4-treatment cross-over design with a
sample of 12 subjects measured at 4 time points achieves 80% power to detect treatment
differences among the means at a 0.05 significance level. The standard deviation across
subjects for cPLI (primary aim) at the same time point is assumed to be 75 ng/mL. The
pattern of the covariance matrix is to have all correlations equal with a correlation of 0.50
between the first and second time point measurements.
Repeated measures mixed model ANOVA as a crossover design, using a
Kronecker product unstructured covariance matrix, was applied to test the within subject
effects of treatment and time on cPLI, gastrin, amylase, CCK, cholesterol, triglycerides
and DGGR lipase. Ranked transformation was applied to cPLI and DGGR lipase to
address non-normal distribution of the residuals. Post hoc pairwise comparisons were run
using Tukey-Kramer adjusted p-values. Shapiro-Wilk tests for normality were used to
evaluate normality of the residuals. All statistical assumptions were sufficiently met.
Statistical analysis was performed using SAS (version 9.4, Cary, North Carolina 27 513,
USA, Release TS1M7). Statistical significance was defined as p<.05.

Results
A total of 14 dogs were enrolled in the study and were determined healthy based
on physical examination. One dog was removed due to diarrhea that occurred while
eating the regular maintenance diet. Another dog was removed for refusing to eat the
MCT treatment diet. No data from these dogs was included in the final analysis. The
mean body weight, body condition score (BCS), and age of the remaining 12 dogs were
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12.14 kg  7.5 and 6/9  , and 5 years   respectively. There were 8 neutered males and
4 spayed females.
There were no treatment effects on cPLI (Figure 6), gastrin, amylase, DGGR
lipase or cholesterol. However, triglyceride concentrations differed significantly by each
treatment at both timepoint 120 minutes and 180 minutes (p<.0001). Triglyceride
concentrations peaked at 120 minutes post-meal for LCSFA (154.65 mg/dL  11.37) and
LCUFA (114.22 mg/dL  10.09), with the largest difference noted at this point, but then
declined toward baseline at 180 minutes after feeding. The high MCT group had
significantly lower triglyceride levels than the long-chain fatty acid groups at 120
minutes (58.9 mg/dL  4.92), but failed to reach its peak by the 180 minute timepoint
(76.76 mg/dL  ). As expected, the low-fat control diet had the lowest 120-minute
triglyceride concentration at 43.18 mg/dL  3.13. (Figure 5). CCK also showed no
treatment or time effect in the study. This finding combined with the unexpected
secretion pattern relative to mealtime or composition questions the validity of the assay
and the CCK results are therefore considered unreliable without additional validation of
the assay kit.

Discussion
In human studies, medium chain triglycerides (MCT) are more rapidly absorbed
and result in less pancreatic enzyme release compared to long chain fatty acids. The goal
of this study was to determine if this same effect occurs in dogs by measuring markers of
exocrine pancreatic stimulation87. Based on our results, the replacement of LCFA with
MCT has little effect on pancreatic lipase release in healthy dogs.
There are several explanations for this observation. Although MCT is expected to
be broken down and absorbed in the small intestine without stimulating pancreatic lipase,
the present experiment had to use a combination of LCSFA and MCT in the high MCT
group due to the poor palatability of MCT alone. The addition of LCFA may have
produced enough gastrin and pancreatic lipase release to confound the effects of MCT.
Unfortunately, the CCK ELISA assay in this study could not be validated with
recombinant canine CCK. Thus, the effects of MCT on this important hormone can not
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be confidently assessed. In addition, this study used healthy dogs with presumably
normal pancreatic function. The influence of dietary fat may be less pronounced in this
population. A previous study has fed healthy dogs a diet with less percentage by weight
of crude fat with extra pancreatic enzymes and MCTs. It concluded that the diet with
MCT and supplemental pancreatic enzymes improved the pancreatic response from
healthy dogs in terms of a noticeably lower cPLI marker, but the difference was not
statistically significant enough (P= 0.2)99. In both the present study and the previously
mentioned study, healthy dogs were the subjects tested. Despite high fatty acid intake, the
healthy pancreas can release appropriate amounts of enzymes. Alterations in the dietary
fatty acid composition in dogs with chronic pancreatitis may yield different results.
cPLI was the main marker used to measure pancreatic enzyme stimulation
activity, and has been reported as a reliable marker when samples were collected at 2, 3,
and 4 hours with 88% to 100% sensitivity100 for both cPLI and triglycerides, respectively.
In a prior study, gastrin concentrations peaked at 30 minutes post-prandial and remained
elevated for at least 2 hours following a meal101. Those findings were used to determine
optimal blood sampling times in this study.
Considering cPLI had no significant changes, it is unsurprising that amylase and
gastrin also demonstrated minimal change. Changes in amylase concentration tend to
parallel the pancreatic lipase level in dogs with pancreatitis102. In addition, gastrin and
amylase secretion is not stimulated by fatty acids alone and may have been impacted by
the protein and carbohydrates within the test diets.
The anticipatory effect of the cephalic phase of digestion could also have
influenced the time effect of dietary treatments, and was not considered in the
experimental design. There are three main phases of gastrointestinal peptides secretion
and activity in response to a meal: the cephalic phase, gastric phase and intestinal phase.
The cephalic phase occurs when dogs smell, sight, or taste leads to anticipation of food
intake; these sensations could also bring the first phase of pancreatic secretion103 to
enhance the efficiency of future digestion104. CCK, gastrin, lipase, and pancreatic
polypeptides are all known to be secreted in response to the cephalic phase104. CCK is
primarily secreted in the duodenum after food intake but is also released from the central
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nervous system to act as neurotransmitter. During the present experiment, there was
advanced preparation of food prior to it being offered to the dogs. Because all of the dogs
were living in the same unit, once one dog had been fed and the blood drawn, other dogs
in the same unit were able to smell the food and anticipate being fed. This could have
created an anticipatory period of feeding for them. Since CCK is secreted during the
cephalic phase of digestion, it makes sense that the baseline CCK could become elevated
sooner and exceed the levels found at 120 minutes. Previous research has found that
beagle dogs had normal serum CCK levels around 5-10pg/mL, with the peak at 45
minutes to 90 minutes, returning to baseline 4 hours post-prandial39,105. This study’s
blood sampling time points were 30 minutes, 120 minutes and 180 minutes; there is a
possibility that CCK levels raised to detectable peak levels post-prandial and were missed
at the blood collection time points.
The only marker found to have significantly changed between different
treatments was the serum triglycerides level. Within the gastrointestinal tract, MCT and
LCT are digested to their respective fatty acids; however, LCFA are repackaged as LCT
into chylomicrons for transport via the lymphatic system via the peripheral circulation.
Medium-chain fatty acids (MCFA), because of their shorter chain lengths, do not require
chylomicron formation for their absorption and transport106. Therefore, MCFA travel
directly to the liver via the portal circulation, bypassing peripheral tissues such as adipose
tissue. The different mode of transport for MCT compared to LCT allows for quicker
absorption and utilization of MCT. MCFA are mostly oxidized by the liver for use as
energy sources and therefore have been reported to act more like glucose than fats107.
The findings of this study are similar to previous research in humans which demonstrated
that even though MCT produced less triglycerides levels in serum, the chylomicron
triglycerides levels still contained a large amount of medium-chain fatty acids92. Thus,
there was little effect of MCT on total cholesterol, but significantly lower triglyceride
concentrations. Since there is a significant decrease of serum triglycerides levels in the
high MCT group compared to the LCSFA and LCUFA groups, this diet might be
applicable to helping with hyperlipidemia and hypertriglyceridemia in dogs and warrants
further research.
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In the current study, all treatments demonstrated peak triglyceride levels within
180 minutes except the high MCT group. The reason for this peak delay could be because
MCT are directly absorbed into the blood stream then move to the liver to be packed into
long chain-fatty acid pool after a series of transformations, and then packed into
chylomicrons and released out of the liver for usage90. Even though MCT is absorbed
faster than LCT, the process of MCT being packed into chylomicron is longer than LCT,
therefore, it takes longer for MCT to reach the peak level.

Conclusion
Using MCT compared to long chain saturated or unsaturated fatty acids as the
fatty acid source reduced post-prandial triglyceride levels in dogs, which could prove
helpful in managing hyperlipidemia and hypertriglyceridemia. In terms of decreasing
pancreatic enzymes release, MCT supplementation does not seem to have a significant
effect in pancreatic enzyme secretion in healthy dogs. In order to help dogs with
pancreatitis, future research should focus on MCT as the dietary fatty acids source in
dogs with clinical pancreatitis to better evaluate the potential impacts.
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APPENDIX

Table 1 Nutrient profile of diets (grams/1000Kcal)
Nutrient

Control

LCSFA

LCUFA

High MCT

Protein

116

60

60

60

Total fat

4

57

57

56

Carbohydrate

115

59

59

60

PUFA

1.4

2.7

16.1

1.7

MUFA

0.8

16.2

35.1

8.1

MCT

0

5.6

0

31.5

Saturated FA

0.8

35.2

4.5

44.5

LCSFA: long chain saturated fatty acids group; LCUFA: long chain unsaturated fatty
acids group; High MCT: high medium chain triglycerides; PUFA: polyunsaturated fatty
acids; MUFA: monounsaturated fatty acids; MCT: medium chain triglycerides.
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Table 2 Treatment distribution and timetable
Week 1
Group

Monday

Tuesday

Wednesday

Thursday

1

High MCT

LCSFA

2

LCSFA

Control

Friday

3

Control

LCUFA

4

LCUFA

High MCT

Week 2
Group

Monday

Tuesday

Wednesday

Thursday

1

Control

LCUFA

2

LCUFA

High MCT

Friday

3

High MCT

LCSFA

4

LCSFA

Control
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Table 3 cPLI mean data (ng/mL)
Analysis Variable: cPLI
treatment
LCSFA

LCUFA

Control

High MCT

time N Obs

N

Mean Std Dev

Minimum

Maximum

0

12

12

46.67

26.84

30

128

30

12

12

47.42

26.81

29

121

120

12

12

49.50

29.71

30

138

180

12

12

52.42

34.16

29

152

0

12

12

44.33

22.90

29

111

30

12

12

44.67

25.21

29

115

120

12

12

52.08

26.57

29

119

180

12

12

47.92

21.86

31

103

0

12

12

44.33

20.56

29

101

30

12

12

46.67

32.91

29

147

120

12

12

56.00

47.38

29

199

180

12

12

54.58

47.90

29

196

0

12

12

42.58

13.14

29

70

30

12

12

43.33

12.77

29

70

120

12

12

45.75

13.87

29

73

180

12

12

44.67

12.32

31

70
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Table 4 Gastrin mean data (ng/L)
Analysis Variable: Gastrin
treatment
LCSFA

LCUFA

Control

High MCT

time N Obs

N

Mean Std Dev

Minimum

Maximum

0

12

12

13.59

3.85

7.07

19.7

30

12

12

14.30

4.43

7.07

20.9

120

12

12

14.62

3.84

7.07

20.7

180

12

12

14.21

4.91

7.07

23.3

0

12

12

12.69

3.80

7.07

19.7

30

12

12

13.36

4.71

7.07

24.4

120

12

12

13.89

4.72

7.07

23.9

180

12

12

13.47

5.00

7.07

21.7

0

12

12

14.08

5.76

7.07

26.4

30

12

12

15.71

8.45

7.07

39.4

120

12

12

13.32

3.70

7.07

20.3

180

12

12

12.91

4.51

7.07

20.9

0

12

12

13.15

3.93

7.07

17.4

30

12

12

14.43

4.41

7.07

20.1

120

12

12

13.50

4.62

7.07

23.7

180

12

12

12.25

4.16

7.07

17.2
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Table 5 CCK mean data (pg/mL)

Analysis Variable: CCK
treatment

time

N Obs

N

Mean

Std Dev

Minimum

Maximum

LCSFA

0

12

12

14.02

6.34

7.65

26.58

30

12

12

14.31

7.08

7.53

26.11

120

12

12

12.74

5.99

6.91

26.58

180

12

12

13.06

7.35

6.58

30.64

0

12

12

13.14

5.84

7.12

26.49

30

12

12

14.79

7.28

7.78

25.74

120

12

12

12.36

5.90

5.51

26.11

180

12

12

13.04

5.84

6.92

22.34

0

12

12

13.69

6.29

7.12

26.58

30

12

12

14.10

7.16

7.71

29.03

120

12

12

12.87

5.71

7.10

22.81

180

12

12

14.19

7.83

6.89

30.36

0

12

12

13.12

6.25

7.65

29.04

30

12

12

13.84

7.14

7.72

29.89

120

12

12

12.09

5.71

7.10

25.64

180

12

12

12.66

7.70

5.89

32.53

LCUFA

Control

High MCT
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Table 6 DGGR lipase mean data (IU/L)
Analysis Variable: DGGR lipase
treatment

time

N Obs

N

Mean

Std Dev

Minimum

Maximum

LCSFA

0

12

11

57.86

47.35

22.03

195.49

30

12

11

57.96

48.26

22.94

197.94

120

12

12

60.04

48.81

23.4

204.52

180

12

12

60.64

49.66

22.64

204.67

0

12

12

51.21

36.75

27.84

161.23

30

12

12

53.53

41.78

26.31

179.89

120

12

12

56.60

40.05

29.22

174.99

180

12

12

54.99

36.60

26.62

161.84

0

12

12

54.48

38.99

23.86

169.33

30

12

12

57.92

52.20

24.78

217.82

120

12

12

66.27

64.38

24.93

257.6

180

12

12

63.48

59.75

22.64

237.4

0

12

12

52.07

26.54

22.49

110.14

30

12

12

52.99

28.76

22.18

118.55

120

12

12

54.14

30.10

22.18

118.7

180

12

12

53.30

28.06

23.56

108.91

LCUFA

Control

High MCT
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Table 7 Amylase mean data (U/dL)
Analysis Variable: Amylase
treatment

time

N Obs

N

Mean

Std Dev

Minimum

Maximum

LCSFA

0

12

12

522.83

123.02

377

789

30

12

12

507.50

117.90

373

759

120

12

12

503.58

117.68

354

713

180

12

12

500.42

111.21

368

689

0

12

12

500.33

106.23

362

693

30

12

12

499.00

109.81

343

704

120

12

12

498.42

106.33

349

679

180

12

12

490.17

96.14

359

684

0

12

12

509.17

106.45

329

725

30

12

12

498.67

112.39

323

702

120

12

12

505.25

114.17

358

723

180

12

12

505.75

113.44

331

704

0

12

12

525.75

126.02

363

778

30

12

12

518.25

126.75

357

783

120

12

12

502.08

113.99

351

722

180

12

12

516.08

124.52

363

767

LCUFA

Control

High MCT
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Table 8 Cholesterol mean data (mg/dL)
Analysis Variable: Cholesterol
treatment

time

N Obs

LCSFA

0

LCUFA

Control

High MCT

N

Mean

Std Dev

Minimum

12

12 212.06

36.53

143.03

283.9

30

12

12 206.16

41.07

140.9

275.91

120

12

12 199.36

38.13

140.5

278.44

180

12

12 195.44

38.07

138.28

265.23

0

12

12 198.71

29.68

148.57

244.8

30

12

12 199.11

33.57

148.42

246.95

120

12

12 190.53

30.08

143.43

238.47

180

12

12 186.48

30.20

143.99

235.39

0

12

12 207.22

32.10

154.27

262.06

30

12

12 198.49

33.94

145.96

247.9

120

12

12 192.56

32.20

136.54

239.03

180

12

12 191.41

32.77

141.13

244.25

0

12

12 205.99

31.26

159.34

258.82

30

12

12 201.33

33.04

150.55

248.76

120

12

12 194.72

33.58

140.66

238.63

180

12

12 196.92

32.36

137.65

246.71
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Maximum

Table 9 Triglycerides mean data (mg/dL)
Analysis Variable: Triglycerides
treatment

time

N Obs

N

LCSFA

0

12

11

30

12

120

LCUFA

Control

High MCT

Mean

Std Dev

Minimum

52.74

19.56

31.3

87.9

11

47.94

12.60

33.15

68.51

12

12

154.65

39.37

98.96

226.64

180

12

12

136.99

43.65

68.79

246.21

0

12

12

50.54

15.59

31.92

88.85

30

12

12

50.33

17.06

29.98

82.97

120

12

12

114.22

34.94

63.85

175.09

180

12

12

108.47

36.07

56.18

155.55

0

12

12

55.30

16.67

34.66

89.06

30

12

12

46.69

18.12

28.1

84.67

120

12

12

43.18

10.84

32.23

65.02

180

12

12

42.20

10.49

27.66

67.59

0

12

12

50.33

14.94

31.23

87

30

12

12

40.61

11.39

30.03

71.6

120

12

12

58.90

17.04

40.9

90.33

180

12

12

76.76

18.52
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112.83

43

Maximum

Figure 1 The homologous bioactive sequence of cholecystokinin and gastrin, modified
from Jens FR et al (2007) 42
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Figure 2 Structure examples of a medium chain fatty acid and triglycerides, modified
from Cassiday L (2016) 108
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Figure 3 Structure example of long chain fatty acid, modified from Epomedicine (2022)
109
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High MCT
Overnight Fast

Baseline Sample
Collection

Feed with 1/2 MCT
and 1/2 butter added

Sample collection at
30, 120, 180 minutes

3-4 days on standard diet

LCSFA
Overnight Fast

Baseline Sample
Collection

Feed with butter
added

Sample collection at
30, 120, 180 minutes

3-4 days on standard diet

Control
Overnight Fast

Baseline Sample
Collection

Feed without oil
added

Sample collection at
30, 120, 180 minutes

3-4 days on standard diet

LCUFA
Overnight Fast

Baseline Sample
Collection

Feed with canola
added

Figure 4 Flow chart process of treatments (example as Group 1)
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Sample collection at
30, 120, 180 minutes

*

*

Figure 5 Mean triglycerides level of treatment groups over time: The high MCT group
had lower serum triglyceride levels than the LCSFA and LCUFA at times 120 and 180
minutes (p<.001).
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cPLI Mean by Treatment and Time
cPLI Mean (ng/mL)
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Figure 6 cPLI mean by treatment and time: There were no statistical differences in serum
cPLI between treatment groups at any timepoint. However, overall cPLI concentrations
demonstrated a mild increase over time with 30 minutes being lower than 120 minutes
(p<.004).
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